In a new Ipsos survey of nearly 20,000 adults from 27 countries on behalf of the World Economic Forum, 74% say they would get a vaccine for COVID-19 if it were available. However, 59% do not expect this will be an option before the end of this year. The reason most commonly given by those who would not get a vaccine is worry about side effects (56%), followed by doubt about its effectiveness (29%).
Intentions to get vaccinated against COVID-19
Globally, 74% of all adults surveyed agree that, “if a vaccine for COVID-19 were available, I would get it”. However, only 37% strongly agree while 37% somewhat agree. Overall, 26% disagree (15% somewhat disagree and 12% strongly disagree).
In most countries, those who agree outnumber those who disagree by a significant margin (more
than 50 percentage points in 12 out of 27 countries).
• The countries where Covid-19 vaccination intent is highest are: China (97%), Brazil (88%),
Australia (88%), and India (87%), Canada (76%)
• Those where it is lowest are: Russia (54%), Poland (56%), Hungary (56%), and France
Reasons for not taking a vaccine
The nearly 5,000 adults surveyed who do not intend to take a vaccine for COVID-19 were asked why they would not do so. In every one of the 27 countries, the #1 reason is worry about the side effects, cited by 56% globally (from 70% in Spain and 68% in Sweden to 41% in Argentina and 40% in Saudi Arabia).
The second-most common reason for not wanting to take a COVID-19 vaccine is doubt about its
effectiveness, cited by 29% globally (from as many as 44% in Russia and Poland to just 12% in
China and 9% in Mexico).
The third most common reason is the perception of not being enough at risk from COVID-19, cited by 19% globally. Among those who are reluctant to be vaccinated, this view is most prevalent in India (37%), Malaysia (36%) and Sweden (35%), while it is least so in Italy (7%) and Brazil (10%).
General opposition to vaccines is cited by 17% of those who would not get a COVID-19 vaccine
globally, but as many as 30% in Russia and Italy.
These are the results of a survey conducted by Ipsos between July 24 and August 7, 2020, on its
Global Advisor online survey platform among a total of 19,519 adults, aged 18-74 in the United States, Canada, Malaysia, South Africa, and Turkey, and aged 16-74 in 22 other countries.
In Canada, the Prime Minister, Justin Trudeau, announced on August 31 that agreements in principle have been reached with Johnson & Johnson and Novavax to procure millions of doses of experimental COVID–19 vaccines. These agreements add to those already reached with Pfizer and Moderna, which were made following the recommendations of the COVID-19 Vaccine Task Force.
“As we continue to work together to limit the impact of the COVID-19 pandemic on the health of Canadians, as well as its social and economic effects, we must also maximize our chances of defeating the virus. To do this, we need to invest in the development of several promising vaccines and ensure that we can manufacture and distribute the vaccine to as many Canadians as possible, as quickly as possible. That is how we will move forward on a sustainable path to a full recovery.” said the Canadian Prime Minister, Justin Trudeau.
The information, facts, analysis, commentary or opinions relating to trending news, appearing in articles on this website do not reflect the views of this website and its management team, and we do not assume any responsibility or liability.